ArticleThorax2018
Microbiome in lung explants of idiopathic pulmonary fibrosis: a case-control study in patients with end-stage fibrosis.
Article in Thorax, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease-A Systematic Review.Biomolecules · 2024Pooled it
- Mechanisms and markers of lung ageing in health and disease.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Influence of stage-specific and location-related intratumoral microbiota on prognosis and metabolic reprogramming in non-small cell lung cancer.Frontiers in immunology · 2025Article
- Persistent microbial infections and idiopathic pulmonary fibrosis - an insight intoFrontiers in cellular and infection microbiology · 2024Review
- Subtype-Based Microbial Analysis in Non-small Cell Lung Cancer.Tuberculosis and respiratory diseases · 2023Article
- Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis.ERJ open research · 2023Article
- Article
- Multi-center evaluation of baseline neutrophil-to-lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in idiopathic pulmonary fibrosis.EClinicalMedicine · 2023Article
- The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review.Translational lung cancer research · 2022Review
- Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases.International journal of molecular sciences · 2022Review
- Essential role of IL-17 in acute exacerbation of pulmonary fibrosis induced by non-typeableTheranostics · 2022Article
- The lung microbiome in end-stage Lymphangioleiomyomatosis.Respiratory research · 2021Article
- The lung microbiome: progress and promise.The Journal of clinical investigation · 2021Review
- Article
- Development of a robust protocol for the characterization of the pulmonary microbiota.Communications biology · 2021Article
- Lung Tissue Microbiome Is Associated With Clinical Outcomes of Idiopathic Pulmonary Fibrosis.Frontiers in medicine · 2021Article
- Non-small cell lung cancer microbiota characterization: Prevalence of enteric and potentially pathogenic bacteria in cancer tissues.PloS one · 2021Article
- Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor Lungs.Frontiers in cellular and infection microbiology · 2021Article
- Molecular approach to the classification of chronic fibrosing lung disease-there and back again.Virchows Archiv : an international journal of pathology · 2021Review
- The evolving role of the lung microbiome in pulmonary fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
The microbiome has been proposed to play a role in the progression of idiopathic pulmonary fibrosis (IPF) based on bronchoalveolar lavage analyses, but the microbiome of lung tissue in IPF has not been explored. In a case-control study of lung explants analysed by 16S rRNA gene sequencing, we could not reliably detect bacterial DNA in basilar tissue samples from patients with either chronic or acute exacerbations of IPF, in contrast to control candidate-donor lungs or cystic fibrosis explants. Thus, our data do not indicate microbiome alterations in regions of IPF lung with advanced fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.